

# Andreas von Deimling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5202317/publications.pdf>

Version: 2024-02-01

716  
papers

91,829  
citations

576

129  
h-index

475

277  
g-index

735  
all docs

735  
docs citations

735  
times ranked

64260  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. <i>Neuro-Oncology</i> , 2023, 25, 263-276.	0.6	23
2	Integrative analysis reveals early and distinct genetic and epigenetic changes in intraductal papillary and tubulopapillary cholangiocarcinogenesis. <i>Gut</i> , 2022, 71, 391-401.	6.1	21
3	Fibroblast Activation Protein- Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases and Lung Cancer: A Translational Exploratory Study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 127-133.	2.8	72
4	Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations. <i>Journal of Pathology</i> , 2022, 256, 61-70.	2.1	12
5	Impact of the methylation classifier and ancillary methods on CNS tumor diagnostics. <i>Neuro-Oncology</i> , 2022, 24, 571-581.	0.6	39
6	Primary central nervous system sarcoma with DICER1 mutation treatment results of a novel molecular entity in pediatric Peruvian patients. <i>Cancer</i> , 2022, 128, 697-707.	2.0	14
7	Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 116-128.	3.2	8
8	T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas. <i>Clinical Cancer Research</i> , 2022, 28, 378-389.	3.2	11
9	DNA methylation-based classification of malformations of cortical development in the human brain. <i>Acta Neuropathologica</i> , 2022, 143, 93-104.	3.9	18
10	Intracranial mesenchymal tumors with FET-CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. <i>Brain Pathology</i> , 2022, 32, e13037.	2.1	11
11	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. <i>Acta Neuropathologica Communications</i> , 2022, 10, 5.	2.4	12
12	Prognostic impact of genetic alterations and methylation classes in meningioma. <i>Brain Pathology</i> , 2022, 32, e12970.	2.1	27
13	DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome including in elderly patients. <i>Acta Neuropathologica Communications</i> , 2022, 10, 39.	2.4	6
14	Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study. <i>Acta Neuropathologica</i> , 2022, 143, 609-612.	3.9	19
15	Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract. <i>Journal of Pathology</i> , 2022, 257, 140-145.	2.1	9
16	Comprehensive profiling of myxopapillary ependymomas identifies a distinct molecular subtype with relapsing disease. <i>Neuro-Oncology</i> , 2022, 24, 1689-1699.	0.6	11
17	Adult cerebellar glioblastoma categorized into a pediatric methylation class with a unique radiological and histological appearance: illustrative case. <i>Journal of Neurosurgery Case Lessons</i> , 2022, 3, .	0.1	0
18	Methylation classifiers: Brain tumors, sarcomas, and what's next. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 346-355.	1.5	16

#	ARTICLE	IF	CITATIONS
19	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial. <i>Clinical Cancer Research</i> , 2022, 28, 2527-2535.	3.2	27
20	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. <i>Cancer Discovery</i> , 2022, 12, 331-355.	7.7	70
21	Oligosarcomas, IDH-mutant are distinct and aggressive. <i>Acta Neuropathologica</i> , 2022, 143, 263-281.	3.9	18
22	Osteosarcoma: Novel prognostic biomarkers using circulating and cell-free tumour DNA. <i>European Journal of Cancer</i> , 2022, 168, 1-11.	1.3	8
23	Endometrial Stromal Sarcomas With BCOR Internal Tandem Duplication and Variant BCOR/BCORL1 Rearrangements Resemble High-grade Endometrial Stromal Sarcomas With Recurrent CDK4 Pathway Alterations and MDM2 Amplifications. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1142-1152.	2.1	10
24	HIP1R and Vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma. <i>Neuro-Oncology</i> , 2022, , .	0.6	4
25	Diagnostic potential of extracellular vesicles in meningioma patients. <i>Neuro-Oncology</i> , 2022, 24, 2078-2090.	0.6	6
26	OTHR-41. Amplification of the PLAG family genes “ PLAGL1 and PLAGL2 “ is a key feature of a novel embryonal CNS tumor type. <i>Neuro-Oncology</i> , 2022, 24, i156-i156.	0.6	1
27	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. <i>Neuro-Oncology</i> , 2022, 24, i107-i107.	0.6	1
28	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. <i>Neuro-Oncology</i> , 2022, 24, i154-i154.	0.6	0
29	LGG-17. Preventing recurrence: targeting molecular mechanisms driving tumor growth rebound after MAPKi withdrawal in pediatric low-grade glioma. <i>Neuro-Oncology</i> , 2022, 24, i91-i91.	0.6	0
30	LGG-18. Inhibition of Bcl-xL targets the senescent compartment of pilocytic astrocytoma. <i>Neuro-Oncology</i> , 2022, 24, i91-i92.	0.6	0
31	LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients. <i>Neuro-Oncology</i> , 2022, 24, i90-i90.	0.6	1
32	DNA-methylome-assisted classification of patients with poor prognostic subventricular zone associated IDH-wildtype glioblastoma. <i>Acta Neuropathologica</i> , 2022, 144, 129-142.	3.9	5
33	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy “ Results of the MET-HIT2000-BIS4 trial. <i>Neuro-Oncology</i> , 2022, 24, i104-i104.	0.6	1
34	AAMP is a binding partner of costimulatory human B7-H3. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	4
35	Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression. <i>Acta Neuropathologica</i> , 2022, 144, 339-352.	3.9	5
36	The molecular evolution of glioblastoma treated by gross total resection alone. <i>Neuro-Oncology</i> , 2021, 23, 334-336.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. <i>Acta Neuropathologica</i> , 2021, 141, 85-100.	3.9	52
38	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 170-186.	12.5	826
39	Accurate calling of <i>KIAA1549</i> – <i>BRAF</i> fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 406-414.	1.8	12
40	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i> . <i>Neuro-Oncology</i> , 2021, 23, 34-43.	0.6	75
41	Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with <i>FOXR2</i> -activation. <i>Acta Neuropathologica Communications</i> , 2021, 9, 20.	2.4	23
42	Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with <i>VEGFA</i> as potent prognostic indicator. <i>Neuro-Oncology</i> , 2021, 23, 1576-1585.	0.6	7
43	G3BPs tether the TSC complex to lysosomes and suppress mTORC1 signaling. <i>Cell</i> , 2021, 184, 655-674.e27.	13.5	65
44	Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma. <i>Nature Communications</i> , 2021, 12, 1014.	5.8	81
45	The age of adult pilocytic astrocytoma cells. <i>Oncogene</i> , 2021, 40, 2830-2841.	2.6	6
46	A vaccine targeting mutant IDH1 in newly diagnosed glioma. <i>Nature</i> , 2021, 592, 463-468.	13.7	232
47	Telomerase reverse transcriptase promoter mutation and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link?. <i>European Journal of Cancer</i> , 2021, 147, 84-94.	1.3	10
48	Diagnostic biomarkers from proteomic characterization of cerebrospinal fluid in patients with brain malignancies. <i>Journal of Neurochemistry</i> , 2021, 158, 522-538.	2.1	18
49	Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype. <i>Acta Neuropathologica</i> , 2021, 141, 971-974.	3.9	12
50	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. <i>Acta Neuropathologica</i> , 2021, 142, 179-189.	3.9	24
51	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. <i>Neuro-Oncology</i> , 2021, 23, 1547-1559.	0.6	34
52	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas. <i>Cancer Discovery</i> , 2021, 11, 2230-2247.	7.7	39
53	Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct <i>DICER1</i> -associated subgroup. <i>Modern Pathology</i> , 2021, 34, 1558-1569.	2.9	28
54	Deep Neural Network for Differentiation of Brain Tumor Tissue Displayed by Confocal Laser Endomicroscopy. <i>Frontiers in Oncology</i> , 2021, 11, 668273.	1.3	7

#	ARTICLE	IF	CITATIONS
55	Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas. <i>Nature Cancer</i> , 2021, 2, 723-740.	5.7	110
56	Loss of H3K27me3 in meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1282-1291.	0.6	45
57	<scp>DNA</scp> methylation-based profiling of bone and soft tissue tumours: a validation study of the â€ˆ<scp>DKFZ</scp> Sarcoma Classifierâ€™™. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 350-360.	1.3	25
58	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <i>Neuro-Oncology</i> , 2021, 23, 1231-1251.	0.6	4,534
59	EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY. <i>Neuro-Oncology</i> , 2021, 23, i10-i10.	0.6	0
60	Myxoid pleomorphic liposarcomaâ€™a clinicopathologic, immunohistochemical, molecular genetic and epigenetic study of 12 cases, suggesting a possible relationship with conventional pleomorphic liposarcoma. <i>Modern Pathology</i> , 2021, 34, 2043-2049.	2.9	24
61	Molecular characterisation of sporadic endolymphatic sac tumours and comparison to von Hippelâ€™Lindau disease-related tumours. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 756-767.	1.8	2
62	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. <i>Neuro-Oncology</i> , 2021, 23, 1597-1611.	0.6	22
63	EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM. <i>Neuro-Oncology</i> , 2021, 23, i47-i48.	0.6	0
64	EPEN-03. ZFTA/C11ORF95 FUSIONS DRIVE SUPRATENTORIAL EPENDYMOMA VIA SHARED ONCOGENIC MECHANISMS. <i>Neuro-Oncology</i> , 2021, 23, i13-i14.	0.6	1
65	Development of Randomized Trials in Adults with Medulloblastomaâ€™The Example of EORTC 1634-BTG/NOA-23. <i>Cancers</i> , 2021, 13, 3451.	1.7	8
66	Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. <i>Modern Pathology</i> , 2021, 34, 2122-2129.	2.9	17
67	<sup>68</sup> Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas â€™Imaging analysis and histological validation. <i>Radiotherapy and Oncology</i> , 2021, 160, 192-201.	0.3	40
68	Molecular diagnostics in drug-resistant focal epilepsy define new disease entities. <i>Brain Pathology</i> , 2021, 31, e12963.	2.1	13
69	DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 834-846.	1.2	7
70	Intrathecal activation of CD8 <sup>+</sup> memory T cells in IgG4-related disease of the brain parenchyma. <i>EMBO Molecular Medicine</i> , 2021, 13, e13953.	3.3	6
71	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. <i>Acta Neuropathologica</i> , 2021, 142, 841-857.	3.9	36
72	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021, 142, 827-839.	3.9	33

#	ARTICLE	IF	CITATIONS
73	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	7.7	110
74	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	3.9	34
75	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. <i>Nature Communications</i> , 2021, 12, 5530.	5.8	24
76	Comparative evaluation of T cell receptors in experimental glioma-draining lymph nodes. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab147.	0.4	1
77	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. <i>Acta Neuropathologica</i> , 2021, 142, 1065-1069.	3.9	16
78	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	5.8	237
79	Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma. <i>Theranostics</i> , 2021, 11, 9217-9233.	4.6	16
80	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. <i>Acta Neuropathologica</i> , 2021, 141, 281-290.	3.9	31
81	The anesthetist's choice of inhalational vs. intravenous anesthetics has no impact on survival of glioblastoma patients. <i>Neurosurgical Review</i> , 2021, 44, 2707-2715.	1.2	9
82	Genetic and epigenetic characterization of posterior pituitary tumors. <i>Acta Neuropathologica</i> , 2021, 142, 1025-1043.	3.9	7
83	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852.	0.8	93
84	PATH-23. OLIGOSARCOMA, IDH-MUTANT IS A DISTINCT AGGRESSIVE TYPE. <i>Neuro-Oncology</i> , 2021, 23, vi119-vi120.	0.6	0
85	NCOG-25. REVISITING THE PIGNATTI RISK SCORE IN LOW-GRADE GLIOMA PATIENTS IN THE MOLECULAR ERA. <i>Neuro-Oncology</i> , 2021, 23, vi157-vi157.	0.6	0
86	PATH-34. MOLECULAR AND CLINICAL HETEROGENEITY WITHIN SPINAL EPENDYMOMAS. <i>Neuro-Oncology</i> , 2021, 23, vi122-vi122.	0.6	0
87	BIOM-39. METHYLATION AND MUTATION PROFILES IN MENINGIOMA CELL-DERIVED EXTRACELLULAR VESICLE DNA REFLECT EPIGENETIC AND GENOMIC ALTERATIONS IN ORIGINAL TUMORS. <i>Neuro-Oncology</i> , 2021, 23, vi19-vi19.	0.6	0
88	PATH-48. RAPID-CNS2: RAPID COMPREHENSIVE ADAPTIVE NANOPORE-SEQUENCING OF CNS TUMORS, A PROOF OF CONCEPT STUDY. <i>Neuro-Oncology</i> , 2021, 23, vi126-vi126.	0.6	0
89	PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. <i>Neuro-Oncology</i> , 2021, 23, vi123-vi124.	0.6	0
90	PATH-46. DIAGNOSTIC IMPACT OF THE CNS TUMOR METHYLATION PROFILING IN A NEUROPATHOLOGY CONSULT PRACTICE. <i>Neuro-Oncology</i> , 2021, 23, vi125-vi126.	0.6	0

#	ARTICLE	IF	CITATIONS
91	DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas. <i>Clinical Cancer Research</i> , 2020, 26, 93-100.	3.2	34
92	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. <i>Acta Neuropathologica</i> , 2020, 139, 193-209.	3.9	83
93	Assessment of Melanin Content and its Influence on Susceptibility Contrast in Melanoma Metastases. <i>Clinical Neuroradiology</i> , 2020, 30, 607-614.	1.0	9
94	Sclerosing epithelioid mesenchymal neoplasm of the pancreas—proposed new entity. <i>Modern Pathology</i> , 2020, 33, 456-467.	2.9	10
95	FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. <i>Acta Neuropathologica</i> , 2020, 139, 175-192.	3.9	15
96	Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. <i>Acta Neuropathologica</i> , 2020, 139, 403-406.	3.9	9
97	T2/FLAIR-mismatch sign for noninvasive detection of IDH-mutant 1p/19q non-codeleted gliomas: validity and pathophysiology. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa004.	0.4	27
98	Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data. <i>Nature Protocols</i> , 2020, 15, 479-512.	5.5	89
99	Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. <i>Acta Neuropathologica</i> , 2020, 139, 277-286.	3.9	36
100	YAP1-fusions in pediatric NF2-wildtype meningioma. <i>Acta Neuropathologica</i> , 2020, 139, 215-218.	3.9	45
101	DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 121-130.	2.7	55
102	Clinicopathologic and molecular features of intracranial desmoplastic small round cell tumors. <i>Brain Pathology</i> , 2020, 30, 213-225.	2.1	20
103	Kaposiform hemangioendothelioma and tufted angioma—(epi)genetic analysis including genome-wide methylation profiling. <i>Annals of Diagnostic Pathology</i> , 2020, 44, 151434.	0.6	16
104	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. <i>Acta Neuropathologica</i> , 2020, 139, 243-257.	3.9	50
105	High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. <i>Pathology Research and Practice</i> , 2020, 216, 152728.	1.0	8
106	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. <i>Acta Neuropathologica</i> , 2020, 139, 583-596.	3.9	13
107	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 97-104.	1.2	29
108	IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. <i>Cell</i> , 2020, 182, 1252-1270.e34.	13.5	259

#	ARTICLE	IF	CITATIONS
109	Mosaic trisomy of chromosome 1q in human brain tissue associates with unilateral polymicrogyria, very early-onset focal epilepsy, and severe developmental delay. <i>Acta Neuropathologica</i> , 2020, 140, 881-891.	3.9	28
110	Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes. <i>Cancer Medicine</i> , 2020, 9, 8373-8385.	1.3	19
111	An activating germline IDH1 variant associated with a tumor entity characterized by unilateral and bilateral chondrosarcoma of the mastoid. <i>Human Genetics and Genomics Advances</i> , 2020, 1, 100006.	1.0	3
112	Infratentorial IDH-mutant astrocytoma is a distinct subtype. <i>Acta Neuropathologica</i> , 2020, 140, 569-581.	3.9	45
113	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , 2020, 297, 164-175.	3.6	19
114	Comparative molecular analysis of primary and recurrent oligodendroglioma that acquired imbalanced 1p/19q codeletion and TP53 mutation: a case report. <i>Acta Neurochirurgica</i> , 2020, 162, 3019-3024.	0.9	3
115	Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7801.	1.8	8
116	Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02. <i>Translational Oncology</i> , 2020, 13, 100852.	1.7	4
117	Molecular characterization of CNS paragangliomas identifies cauda equina paragangliomas as a distinct tumor entity. <i>Acta Neuropathologica</i> , 2020, 140, 893-906.	3.9	19
118	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1. <i>JCO Precision Oncology</i> , 2020, 4, 1280-1284.	1.5	1
119	An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data. <i>Acta Neuropathologica</i> , 2020, 140, 237-239.	3.9	5
120	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , 2020, 22, 1667-1676.	0.6	9
121	Germline <i>SDHB</i> inactivating mutation in gastric spindle cell sarcoma. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 601-608.	1.5	4
122	Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines. <i>Cancers</i> , 2020, 12, 577.	1.7	7
123	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413.	3.9	116
124	Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdz060.	0.4	8
125	Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter methylated malignant astrocytoma. <i>Neuro-Oncology</i> , 2020, 22, 1162-1172.	0.6	42
126	Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas. <i>Nature Communications</i> , 2020, 11, 931.	5.8	112



#	ARTICLE	IF	CITATIONS
127	Interdisciplinary approach allows minimally invasive, nerve-sparing removal of retroperitoneal peripheral nerve sheath tumors. <i>Langenbeck's Archives of Surgery</i> , 2020, 405, 199-205.	0.8	7
128	Analysis of a Surgical Series of 21 Cerebral Radiation Necroses. <i>World Neurosurgery</i> , 2020, 137, e462-e469.	0.7	6
129	Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival. <i>Clinical Cancer Research</i> , 2020, 26, 2231-2243.	3.2	21
130	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. <i>Acta Neuropathologica</i> , 2020, 139, 603-608.	3.9	344
131	Endometrial stromal sarcomas with <i>BCOR</i> rearrangement harbor <i>MDM2</i> amplifications. <i>Journal of Pathology: Clinical Research</i> , 2020, 6, 178-184.	1.3	32
132	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	0.6	543
133	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 2028-2040.	0.8	58
134	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. <i>Brain Pathology</i> , 2020, 30, 844-856.	2.1	363
135	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	7.7	157
136	Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors. <i>Journal of Clinical Investigation</i> , 2020, 130, 2488-2495.	3.9	23
137	The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA10503-LBA10503.	0.8	12
138	Quality assurance in neuropathology: Experiences from the round robin trials on IDH mutation and MGMT promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019. <i>Journal of Clinical Investigation</i> , 2020, 39, 203-211.		3
139	QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA – RESULTS OF THE HIT2000 TRIAL. <i>Neuro-Oncology</i> , 2020, 22, iii433-iii433.	0.6	0
140	MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS. <i>Neuro-Oncology</i> , 2020, 22, iii413-iii413.	0.6	0
141	PATH-04. AN ENHANCED AI-DRIVEN PLATFORM FOR PRECISION MOLECULAR BRAIN TUMOR DIANOSTICS. <i>Neuro-Oncology</i> , 2020, 22, iii425-iii425.	0.6	0
142	PATH-26. RNA SEQUENCING OF FORMALIN-FIXED PARAFFIN-EMBEDDED SPECIMENS IN DIAGNOSTIC ROUTINE IDENTIFIES CLINICALLY RELEVANT GENE FUSIONS. <i>Neuro-Oncology</i> , 2020, 22, iii429-iii430.	0.6	0
143	LGG-33. ISOMORPHIC DIFFUSE GLIOMA HAS RECURRENT GENE FUSIONS OF MYBL1 OR MYB AND CAN BE DISTINGUISHED FROM OTHER MYB/MYBL1 ALTERED GLIOMAS BASED ON A DISTINCT MORPHOLOGY AND DNA METHYLATION PROFILE. <i>Neuro-Oncology</i> , 2020, 22, iii372-iii373.	0.6	0
144	EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2020, 22, iii311-iii311.	0.6	0

#	ARTICLE	IF	CITATIONS
145	MBCL-06. RISK STRATIFICATION IMPROVEMENT OF THE HIT2000 AND I-HIT-MED COHORTS USING MOLECULAR SUBTYPES I-VIII OF GROUP 3/4 MEDULLOBLASTOMAS. <i>Neuro-Oncology</i> , 2020, 22, iii388-iii388.	0.6	0
146	MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN). <i>Neuro-Oncology</i> , 2020, 22, iii410-iii410.	0.6	0
147	PATH-11. PROSPECTIVE (EPI-)GENETIC CLASSIFICATION OF > 1,000 PEDIATRIC CNS TUMORSâ€”THE MNP 2.0 STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii426-iii426.	0.6	0
148	IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation proteinâ€”specific PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2569-2580.	3.3	94
149	Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E. <i>Cancer Research</i> , 2019, 79, 4994-5007.	0.4	28
150	MYCN amplification drives an aggressive form of spinal ependymoma. <i>Acta Neuropathologica</i> , 2019, 138, 1075-1089.	3.9	104
151	Incidence, mortality and outcome of meningiomas: A population-based study from Germany. <i>Cancer Epidemiology</i> , 2019, 62, 101562.	0.8	90
152	Extent of Resection, MGMT Promoter Methylation Status and Tumor Location Independently Predict Progression-Free Survival in Adult Sporadic Pilocytic Astrocytoma. <i>Cancers</i> , 2019, 11, 1072.	1.7	16
153	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. <i>Acta Neuropathologica</i> , 2019, 138, 827-835.	3.9	42
154	Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome. <i>Journal of Neuro-Oncology</i> , 2019, 145, 469-477.	1.4	26
155	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. <i>Acta Neuropathologica Communications</i> , 2019, 7, 163.	2.4	37
156	Primary CNS Alveolar Rhabdomyosarcoma: Importance of Epigenetic and Transcriptomic Assays for Accurate Diagnosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 1073-1075.	0.9	6
157	Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT. <i>Acta Neuropathologica Communications</i> , 2019, 7, 140.	2.4	26
158	Location-Dependent Patient Outcome and Recurrence Patterns in IDH1-Wildtype Glioblastoma. <i>Cancers</i> , 2019, 11, 122.	1.7	25
159	Targeted Genomic Profiling of Acral Melanoma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1068-1077.	3.0	118
160	Advances in multidisciplinary therapy for meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i18-i31.	0.6	102
161	Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas. <i>Clinical Cancer Research</i> , 2019, 25, 5260-5270.	3.2	23
162	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. <i>Acta Neuropathologica</i> , 2019, 138, 497-504.	3.9	57

#	ARTICLE	IF	CITATIONS
163	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	0.6	184
164	GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. <i>Neuro-Oncology</i> , 2019, 21, ii82-ii82.	0.6	2
165	Calcifying fibrous tumor and inflammatory myofibroblastic tumor are epigenetically related: A comparative genome-wide methylation study. <i>Annals of Diagnostic Pathology</i> , 2019, 41, 102-105.	0.6	10
166	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1255-1268.	2.5	45
167	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. <i>Acta Neuropathologica</i> , 2019, 138, 295-308.	3.9	74
168	GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION. <i>Neuro-Oncology</i> , 2019, 21, ii83-ii83.	0.6	1
169	RhoA regulates translation of the Nogo-A decoy SPARC in white matter-invading glioblastomas. <i>Acta Neuropathologica</i> , 2019, 138, 275-293.	3.9	6
170	Impact of post-surgical freezing delay on brain tumor metabolomics. <i>Metabolomics</i> , 2019, 15, 78.	1.4	9
171	Identification of KIF11 As a Novel Target in Meningioma. <i>Cancers</i> , 2019, 11, 545.	1.7	31
172	GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS. <i>Neuro-Oncology</i> , 2019, 21, ii81-ii82.	0.6	0
173	LGG-13. PAPILLARY GLIONEURONAL TUMOR (PGNT) EXHIBITS A CHARACTERISTIC METHYLATION PROFILE AND MANDATORY FUSIONS INVOLVING PRKCA. <i>Neuro-Oncology</i> , 2019, 21, ii101-ii102.	0.6	0
174	Molecular progression of SHH-activated medulloblastomas. <i>Acta Neuropathologica</i> , 2019, 138, 327-330.	3.9	2
175	Association Between Tumor Compartment Volumes, the Incidence of Pretreatment Seizures, and Statin-Mediated Protective Effects in Glioblastoma. <i>Neurosurgery</i> , 2019, 85, E722-E729.	0.6	17
176	DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1273-1281.	1.2	50
177	Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. <i>Acta Neuropathologica Communications</i> , 2019, 7, 24.	2.4	101
178	Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype. <i>Clinical Sarcoma Research</i> , 2019, 9, 2.	2.3	48
179	Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. <i>Cancer Cell</i> , 2019, 35, 692-704.e12.	7.7	172
180	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2019, 20, 728-740.	5.1	271

#	ARTICLE	IF	CITATIONS
181	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. <i>Acta Neuropathologica</i> , 2019, 137, 847-850.	3.9	7
182	CIC protein instability contributes to tumorigenesis in glioblastoma. <i>Nature Communications</i> , 2019, 10, 661.	5.8	63
183	Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. <i>Acta Neuropathologica</i> , 2019, 137, 1003-1015.	3.9	9
184	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. <i>Acta Neuropathologica</i> , 2019, 137, 837-846.	3.9	43
185	Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas. <i>Acta Neuropathologica Communications</i> , 2019, 7, 201.	2.4	13
186	The molecular landscape of ETMR at diagnosis and relapse. <i>Nature</i> , 2019, 576, 274-280.	13.7	94
187	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245.	13.7	637
188	Ectopic intracranial retinoblastoma in a 3.5-month-old infant without eye involvement and without evidence of heritability. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27599.	0.8	3
189	Life after surgical resection of a meningioma: a prospective cross-sectional study evaluating health-related quality of life. <i>Neuro-Oncology</i> , 2019, 21, i32-i43.	0.6	56
190	Characterization of the epithelial membrane protein 3 interaction network reveals a potential functional link to mitogenic signal transduction regulation. <i>International Journal of Cancer</i> , 2019, 145, 461-473.	2.3	9
191	Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. <i>Acta Neuropathologica</i> , 2019, 137, 521-525.	3.9	51
192	Imaging and diagnostic advances for intracranial meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i44-i61.	0.6	100
193	Molecular and translational advances in meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i4-i17.	0.6	92
194	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. <i>Clinical Cancer Research</i> , 2019, 25, 1851-1866.	3.2	55
195	DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. <i>Neuro-Oncology</i> , 2019, 21, 214-221.	0.6	31
196	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 95-105.	0.6	100
197	Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib. <i>Clinical Cancer Research</i> , 2019, 25, 253-265.	3.2	42
198	Identification of New Inhibitors of Mutant Isocitrate Dehydrogenase 2 through Molecular Similarity-based Virtual Screening. <i>Letters in Drug Design and Discovery</i> , 2019, 16, 861-867.	0.4	2

#	ARTICLE	IF	CITATIONS
199	Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study. , 2019, 80, .		0
200	Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma. , 2019, , .		0
201	Abstract B075: Modeling response and resistance to immune checkpoint blockade in syngeneic mouse glioma. , 2019, , .		0
202	Abstract PR15: The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling. , 2019, , .		0
203	Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.. Journal of Clinical Oncology, 2019, 37, 2013-2013.	0.8	0
204	Efficacy of re-irradiation with carbon ions (RiCi) in patients with recurrent high-grade glioma (rHGG) compared to the standard re-irradiation with photons (RiP): The reference multicenter cohort of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).. Journal of Clinical Oncology, 2019, 37, 2057-2057.	0.8	2
205	Abstract 2182: Preclinical in vitro and in vivo combination therapies for mutant IDH1R132 tumors with BAY 1436032. , 2019, , .		0
206	Abstract 3646: (Epi-)genomic homogeneity in radiation-induced glioblastoma with recurrentPDGFRAamplification and loss ofCDKN2A/Bfollowing primary acute lymphatic leukemia and medulloblastoma. , 2019, , .		0
207	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. Acta Neuropathologica, 2018, 136, 153-166.	3.9	298
208	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathologica, 2018, 135, 955-963.	3.9	109
209	Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. Molecular Cancer Research, 2018, 16, 767-776.	1.5	25
210	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 2018, 135, 601-615.	3.9	76
211	IDH1 mutant glioma initiating cells are predisposed to apoptosis under endoplasmic reticulum (ER) stress. Neuro-Oncology, 2018, 20, i13-i13.	0.6	1
212	Diffuse Astrocytoma, IDH-Wildtype: A Dissolving Diagnosis. Journal of Neuropathology and Experimental Neurology, 2018, 77, 422-425.	0.9	57
213	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation in the NCT Neuro Master Match (N2M2) pilot study. Neuro-Oncology, 2018, 20, 826-837.	0.6	32
214	Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 388-393.	1.0	15
215	Rapid detection of 2-hydroxyglutarate in frozen sections of IDH mutant tumors by MALDI-TOF mass spectrometry. Acta Neuropathologica Communications, 2018, 6, 21.	2.4	28
216	DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica, 2018, 136, 255-271.	3.9	59

#	ARTICLE	IF	CITATIONS
217	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	13.7	1,872
218	A PRDX1&#x385; heterodimer amplifies MET&#x2013;driven invasion of <i>IDH</i>-wildtype and <i>IDH</i>-mutant gliomas. <i>International Journal of Cancer</i> , 2018, 143, 1176-1187.	2.3	14
219	Extra-small dual-lumen micro-balloon catheters can improve endovascular embolization: an experimental in vivo and in vitro study. <i>Journal of NeuroInterventional Surgery</i> , 2018, 10, 1092-1096.	2.0	17
220	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. <i>Acta Neuropathologica</i> , 2018, 136, 273-291.	3.9	190
221	Molecular characterization of medulloblastomas with extensive nodularity (MBEN). <i>Acta Neuropathologica</i> , 2018, 136, 303-313.	3.9	20
222	Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma. <i>Clinical Cancer Research</i> , 2018, 24, 2951-2962.	3.2	25
223	Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. <i>Modern Pathology</i> , 2018, 31, 1246-1256.	2.9	76
224	Grading of Diffuse Astrocytic Gliomas: A Review of Studies Before and After the Advent of IDH Testing. <i>Seminars in Neurology</i> , 2018, 38, 019-023.	0.5	30
225	Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. <i>Journal of Neurosurgery</i> , 2018, 128, 1102-1114.	0.9	26
226	Evaluation of a novel liquid embolic agent (precipitating hydrophobic injectable liquid (PHIL)) in an animal endovascular embolization model. <i>Journal of NeuroInterventional Surgery</i> , 2018, 10, 268-274.	2.0	29
227	Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 848-857.	0.6	170
228	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. <i>Brain Pathology</i> , 2018, 28, 656-662.	2.1	89
229	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. <i>Neuro-Oncology</i> , 2018, 20, 367-379.	0.6	79
230	Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. <i>Modern Pathology</i> , 2018, 31, 160-168.	2.9	4
231	Proteomics in Pathology. <i>Proteomics</i> , 2018, 18, 1700361.	1.3	18
232	TBIO-10. PEDIATRIC TARGETED THERAPY 2.0: DEVELOPMENT OF PERSONALIZED PEDIATRIC ONCOLOGY. <i>Neuro-Oncology</i> , 2018, 20, i182-i182.	0.6	0
233	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children&#x2013;s Oncology Group Randomized ACNS0332 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3388-3395.	0.8	58
234	CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi48-vi49.	0.6	0

#	ARTICLE	IF	CITATIONS
235	LGG-11. REGULATION OF ONCOGENE-INDUCED SENESCENCE IN PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2018, 20, i106-i106.	0.6	0
236	TBIO-07. ASSESSING THE UTILITY OF DNA METHYLATION PROFILING IN BRAIN TUMOR DIAGNOSTICSâ€”THE PROSPECTIVE MNP2.0 STUDY. <i>Neuro-Oncology</i> , 2018, 20, i181-i181.	0.6	0
237	cIMPACT-NOW update 3: recommended diagnostic criteria for â€œDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IVâ€. <i>Acta Neuropathologica</i> , 2018, 136, 805-810.	3.9	599
238	Frame-based stereotactic biopsies using an intraoperative MR-scanner are as safe and effective as conventional stereotactic procedures. <i>PLoS ONE</i> , 2018, 13, e0205772.	1.1	11
239	Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1472-1480.	0.4	5
240	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018, 136, 975-978.	3.9	11
241	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. <i>Acta Neuropathologica</i> , 2018, 136, 793-803.	3.9	195
242	Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients. <i>Journal of Neuro-Oncology</i> , 2018, 140, 659-667.	1.4	10
243	Diagnostic accuracy of DW MR imaging in the differentiation of chordomas and chondrosarcomas of the skull base: A 3.0-T MRI study of 105 cases. <i>European Journal of Radiology</i> , 2018, 105, 119-124.	1.2	24
244	Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8981-9003.	2.9	23
245	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. <i>Acta Neuropathologica</i> , 2018, 136, 239-253.	3.9	118
246	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. <i>Acta Neuropathologica</i> , 2018, 136, 293-302.	3.9	56
247	MBCL-21. EARLY CHILDHOOD MEDULLOBLASTOMA: SUBGROUP-SPECIFIC SURVIVAL IN PATIENTS TREATED WITH SYSTEMIC CHEMOTHERAPY AND INTRAVENTRICULAR MTX TO AVOID CRANIOSPINAL RADIOTHERAPY. <i>Neuro-Oncology</i> , 2018, 20, i121-i121.	0.6	0
248	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. <i>Acta Neuropathologica</i> , 2018, 136, 181-210.	3.9	308
249	EGFL7 enhances surface expression of integrin $\alpha 5 \beta 1$ to promote angiogenesis in malignant brain tumors. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	33
250	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. <i>Neuro-Oncology</i> , 2018, 20, 1616-1624.	0.6	65
251	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2132-2145.	2.5	41
252	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. <i>Nature Medicine</i> , 2018, 24, 1192-1203.	15.2	359

#	ARTICLE	IF	CITATIONS
253	BRAF V600E Mutations in Nevi and Melanocytic Tumors of Uncertain Malignant Potential. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2489-2491.	0.3	5
254	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making – A Selected Case Series. <i>Klinische Padiatrie</i> , 2018, 230, 305-313.	0.2	8
255	Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1573-1584.	3.3	18
256	Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. <i>Neuro-Oncology</i> , 2018, 20, 1517-1524.	0.6	36
257	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. <i>Acta Neuropathologica</i> , 2018, 136, 327-337.	3.9	104
258	Integrated Genomic Classification of Melanocytic Tumors of the Central Nervous System Using Mutation Analysis, Copy Number Alterations, and DNA Methylation Profiling. <i>Clinical Cancer Research</i> , 2018, 24, 4494-4504.	3.2	28
259	LGG-20. MOLECULARLY-DEFINED DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) COMPRISES TWO SUBGROUPS WITH DISTINCT CLINICAL AND GENETIC FEATURES. <i>Neuro-Oncology</i> , 2018, 20, i108-i108.	0.6	0
260	Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 1004.	1.4	16
261	GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2000-2000.	0.8	17
262	A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. <i>Journal of Clinical Oncology</i> , 2018, 36, 2001-2001.	0.8	21
263	VXM01 phase I study in patients with progressive glioblastoma: Final results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2017-2017.	0.8	87
264	Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2013-2013.	0.8	0
265	Methylation among members of the PI3K/AKT/mTOR pathway in melanoma brain and extracerebral metastases.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21515-e21515.	0.8	0
266	Towards a molecular algorithm predicting glioma treatment response and resistance: A biomarker analysis and path to real time profiling in N2M2.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12090-12090.	0.8	0
267	Abstract 1906: PFKFB4, much more than just a glycolytic gene. , 2018, , .		0
268	Abstract IA11: Pediatric precision oncology programs in Germany and Europe. , 2018, , .		0
269	IMMU-54. THE ONCOMETABOLITE R-2-HYDROXYGLUTARATE SUPPRESSES THE INNATE IMMUNE MICROENVIRONMENT OF IDH1-MUTATED GLIOMAS VIA ARYL HYDROCARBON RECEPTOR SIGNALING. <i>Neuro-Oncology</i> , 2018, 20, vi133-vi133.	0.6	0
270	Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. <i>Acta Neuropathologica</i> , 2017, 133, 629-644.	3.9	146



#	ARTICLE	IF	CITATIONS
271	H3-IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. <i>Acta Neuropathologica</i> , 2017, 134, 507-516.	3.9	144
272	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. <i>Acta Neuropathologica</i> , 2017, 134, 155-158.	3.9	26
273	Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. <i>Acta Neuropathologica Communications</i> , 2017, 5, 39.	2.4	110
274	Diagnostic challenges in meningioma. <i>Neuro-Oncology</i> , 2017, 19, 1588-1598.	0.6	106
275	Tweety-Homolog 1 Drives Brain Colonization of Gliomas. <i>Journal of Neuroscience</i> , 2017, 37, 6837-6850.	1.7	129
276	Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens. <i>Acta Neuropathologica</i> , 2017, 134, 297-316.	3.9	23
277	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 682-694.	5.1	586
278	Copy number variation analysis and methylome profiling of a GNAQ-mutant primary meningeal melanocytic tumor and its liver metastasis. <i>Experimental and Molecular Pathology</i> , 2017, 102, 25-31.	0.9	15
279	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. <i>Acta Neuropathologica</i> , 2017, 133, 325-327.	3.9	12
280	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. <i>Acta Neuropathologica</i> , 2017, 133, 1-3.	3.9	120
281	Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. <i>Molecular Therapy</i> , 2017, 25, 2620-2634.	3.7	199
282	DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. <i>Acta Neuropathologica</i> , 2017, 134, 965-967.	3.9	38
283	Design, synthesis and biological activity of 3-pyrazine-2-yl-oxazolidin-2-ones as novel, potent and selective inhibitors of mutant isocitrate dehydrogenase 1. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 6379-6387.	1.4	10
284	Report of a Novel Case of Anaplastic Olfactory Groove Meningioma and Its Methylation Subtype. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 997-999.	0.9	0
285	Loss of Mpdz impairs ependymal cell integrity leading to perinatal-onset hydrocephalus in mice. <i>EMBO Molecular Medicine</i> , 2017, 9, 890-905.	3.3	54
286	Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 6846-6855.	3.2	151
287	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	13.7	787
288	Therapeutic radiation for childhood cancer drives structural aberrations of NF2 in meningiomas. <i>Nature Communications</i> , 2017, 8, 186.	5.8	76

#	ARTICLE	IF	CITATIONS
289	GENE-07. MOLECULAR NEUROPATHOLOGY 2.0 - INCREASING DIAGNOSTIC ACCURACY IN PEDIATRIC NEUROONCOLOGY. <i>Neuro-Oncology</i> , 2017, 19, iv19-iv19.	0.6	0
290	Grading of diffuse astrocytic gliomas: Broders, Kernohan, ZÃ¼lch, the WHO and Shakespeare. <i>Acta Neuropathologica</i> , 2017, 134, 517-520.	3.9	15
291	Lomustine and Bevacizumab in Progressive Glioblastoma. <i>New England Journal of Medicine</i> , 2017, 377, 1954-1963.	13.9	670
292	Molecular Transition of an Adult Low-Grade Brain Tumor to an Atypical Teratoid/Rhabdoid Tumor Over a Time-Course of 14 Years. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 655-664.	0.9	13
293	Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. <i>Journal of the National Cancer Institute</i> , 2017, 109, 1-4.	3.0	51
294	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. <i>Clinical Sarcoma Research</i> , 2017, 7, 9.	2.3	51
295	K27M-mutant histone-3 as a novel target for glioma immunotherapy. <i>Oncolmunology</i> , 2017, 6, e1328340.	2.1	74
296	cIMPACT NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46 27, 851-852.	2.1	63
297	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , 2017, 133, 5-12.	3.9	271
298	MNGI-02. PREOPERATIVE EMBOLIZATION OF MENINGIOMA: INFERIOR NEUROLOGICAL OUTCOME, INCREASED RISK OF CARDIOVASCULAR COMPLICATIONS AND SHORTER TIME TO RECURRENCE?. <i>Neuro-Oncology</i> , 2017, 19, vi132-vi132.	0.6	0
299	NIMG-51. RADIOLOGIC PHENOTYPES ARE TREATMENT SPECIFIC AND ASSOCIATED WITH SURVIVAL - EXPLORATORY ANALYSIS OF EORTC 26101. <i>Neuro-Oncology</i> , 2017, 19, vi153-vi153.	0.6	0
300	PATH-24. MOLECULAR SUBGROUPS OF ADULT EPENDYMAL TUMORS: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK. <i>Neuro-Oncology</i> , 2017, 19, vi175-vi176.	0.6	0
301	PDTM-47. CHARACTERIZATION OF THE SENESENCE-ASSOCIATED SECRETORY PHENOTYPE IN PILOCYTIC ASTROCYTOMA AND ITS ROLE IN ONCOGENE-INDUCED SENESENCE. <i>Neuro-Oncology</i> , 2017, 19, vi200-vi200.	0.6	0
302	Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine. <i>International Journal of Molecular Sciences</i> , 2017, 18, 995.	1.8	32
303	PDCT-05. MOLECULAR DIAGNOSTICS REVEAL 60% HIGHER SURVIVAL FOR MOLECULARLY-VERIFIED VERSUS HISTOPATHOLOGICALLY-DIAGNOSED PEDIATRIC SUPRATENTORIAL CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS AND PINEOBLASTOMAS; A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP ACNS0332 TRIAL. <i>Neuro-Oncology</i> , 2017, 19, vi184-vi185.	0.6	2
304	LGG-04. CHARACTERIZATION OF ONCOGENE-INDUCED SENESENCE AND THE ROLE OF THE SENESENCE-ASSOCIATED SECRETORY PHENOTYPE IN PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2017, 19, iv33-iv33.	0.6	0
305	TRTH-09. PTT2.0: DEVELOPING PERSONALIZED PEDIATRIC ONCOLOGY. <i>Neuro-Oncology</i> , 2017, 19, iv53-iv53.	0.6	0
306	ACTR-05. THE RANDOMIZED PHASE II ARTE TRIAL: BEVACIZUMAB PLUS HYPOFRACTIONATED RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi2-vi2.	0.6	3

#	ARTICLE	IF	CITATIONS
307	The INFORM personalized medicine study for high-risk pediatric cancer patients.. Journal of Clinical Oncology, 2017, 35, 10509-10509.	0.8	1
308	VXM01 phase I study in patients with resectable progression of a glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2061-2061.	0.8	4
309	mIDH-associated DNA hypermethylation in acute myeloid leukemia reflects differentiation blockage rather than inhibition of TET-mediated demethylation. Cell Stress, 2017, 1, 55-67.	1.4	3
310	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. Oncotarget, 2017, 8, 11460-11479.	0.8	43
311	Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma.. Journal of Clinical Oncology, 2017, 35, 2013-2013.	0.8	0
312	LG-27DKFZ-BT66 - A NOVEL PILOCYTIC ASTROCYTOMA MODEL FOR PRECLINICAL DRUG TESTING. Neuro-Oncology, 2016, 18, iii84.3-iii84.	0.6	0
313	TB-11 MOLECULAR NEUROPATHOLOGY 2.0 - INCREASING DIAGNOSTIC ACCURACY IN PEDIATRIC NEUROONCOLOGY. Neuro-Oncology, 2016, 18, iii170.4-iii170.	0.6	0
314	TB-14 THE INFORM PERSONALIZED MEDICINE STUDY - NEW MOLECULAR INSIGHTS INTO RELAPSED PEDIATRIC BRAIN TUMORS. Neuro-Oncology, 2016, 18, iii171.1-iii171.	0.6	0
315	Tryptophanâ€2,3â€dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptorâ€4. Journal of Neurochemistry, 2016, 136, 1142-1154.	2.1	48
316	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. Brain Pathology, 2016, 26, 506-516.	2.1	14
317	<i>LOC283731</i> promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients. International Journal of Cancer, 2016, 139, 424-432.	2.3	18
318	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 2016, 18, now133.	0.6	130
319	Differential nuclear <sc>ATRX</sc> expression in sarcomas. Histopathology, 2016, 68, 738-745.	1.6	19
320	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. Brain Pathology, 2016, 26, 199-205.	2.1	39
321	RINT1 functions as a multitasking protein at the crossroads between genomic stability, ER homeostasis, and autophagy. Autophagy, 2016, 12, 1413-1415.	4.3	5
322	Somatic mutations of <i>DICER1</i> and <i>KMT2D</i> are frequent in intraocular medulloepitheliomas. Genes Chromosomes and Cancer, 2016, 55, 418-427.	1.5	34
323	Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone. BMC Medicine, 2016, 14, 170.	2.3	31
324	<i>IDH2</i> Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity. Cancer Research, 2016, 76, 7118-7129.	0.4	99

#	ARTICLE	IF	CITATIONS
325	Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 370-377.	1.2	25
326	Radiotherapy plus concomitant temozolomide in primary gliosarcoma. <i>Journal of Neuro-Oncology</i> , 2016, 128, 341-348.	1.4	26
327	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. <i>Acta Neuropathologica</i> , 2016, 131, 803-820.	3.9	12,144
328	EANO guidelines for the diagnosis and treatment of meningiomas. <i>Lancet Oncology</i> , The, 2016, 17, e383-e391.	5.1	627
329	Identification of a novel selective inhibitor of mutant isocitrate dehydrogenase 1 at allosteric site by docking-based virtual screening. <i>RSC Advances</i> , 2016, 6, 96735-96742.	1.7	13
330	Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2016, 17, 1521-1532.	5.1	396
331	HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2016, 18, iii63.2-iii63.	0.6	0
332	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	1.3	262
333	Evidence of H3 K27M mutations in posterior fossa ependymomas. <i>Acta Neuropathologica</i> , 2016, 132, 635-637.	3.9	73
334	Radiogenomics of Glioblastoma: Machine Learning–based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. <i>Radiology</i> , 2016, 281, 907-918.	3.6	236
335	Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients. <i>BMC Cancer</i> , 2016, 16, 81.	1.1	51
336	Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. <i>Acta Neuropathologica Communications</i> , 2016, 4, 20.	2.4	136
337	Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis. <i>Journal of Neuro-Oncology</i> , 2016, 129, 319-328.	1.4	25
338	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , 2016, 131, 903-910.	3.9	203
339	Methylation-based classification of benign and malignant peripheral nerve sheath tumors. <i>Acta Neuropathologica</i> , 2016, 131, 877-887.	3.9	151
340	Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer. <i>Clinical Neurology and Neurosurgery</i> , 2016, 142, 72-80.	0.6	26
341	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. <i>Neuro-Oncology</i> , 2016, 18, 790-796.	0.6	67
342	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	7.7	438

#	ARTICLE	IF	CITATIONS
343	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	13.5	702
344	TERT Promoter Mutations and Risk of Recurrence in Meningioma. Journal of the National Cancer Institute, 2016, 108, djv377.	3.0	283
345	Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathologica, 2016, 131, 309-319.	3.9	74
346	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathologica, 2016, 131, 137-146.	3.9	162
347	Abstract 2645: BAY 1436032: A highly selective, potent and orally available inhibitor of mutant forms of IDH1. , 2016, , .		1
348	Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma. , 2016, , .		1
349	Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo. Blood, 2016, 128, 745-745.	0.6	7
350	EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma.. Journal of Clinical Oncology, 2016, 34, 2042-2042.	0.8	3
351	A mutation-specific peptide vaccine targeting <i>IDH1R132H</i> in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).. Journal of Clinical Oncology, 2016, 34, TPS2082-TPS2082.	0.8	6
352	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (NÄ²MÄ²).. Journal of Clinical Oncology, 2016, 34, TPS2084-TPS2084.	0.8	4
353	MYCN and HDAC5 transcriptionally repress <i>CD9</i> to trigger invasion and metastasis in neuroblastoma. Oncotarget, 2016, 7, 66344-66359.	0.8	30
354	Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget, 2016, 7, 82028-82045.	0.8	21
355	Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade. Oncotarget, 2016, 7, 14551-14568.	0.8	36
356	Epidermal <i>Nbn</i> deletion causes premature hair loss and a phenotype resembling psoriasiform dermatitis. Oncotarget, 2016, 7, 23006-23018.	0.8	5
357	Abstract 11: Advancing methylation profiling in neuropathology: Diagnosis and clinical management. , 2016, , .		0
358	Abstract 4277: Development and validation of a novel IDH1-mutant astrocyte cell line as a model for high-grade gliomas. , 2016, , .		0
359	Abstract 138: Solid papillary carcinoma with reverse polarization are driven by IDH2 and PI3K pathway mutations. , 2016, , .		1
360	ANGI-08RADIOGENOMIC rCBV-IMAGING VISUALIZES THE DISTINCT ANGIOGENESIS TRANSCRIPTOME SIGNATURES OF IDH MUTANT AND WILD-TYPE GLIOMAS. Neuro-Oncology, 2015, 17, v42.3-v42.	0.6	0

#	ARTICLE	IF	CITATIONS
361	Validation of a Manual Protocol for BRAF V600E Mutation-specific Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 382-388.	0.6	7
362	IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Scientific Reports, 2015, 5, 16238.	1.6	259
363	SURG-16PROGNOSTIC VALUE OF THE EXTENT OF RESECTION AND IDH1 MUTATION STATUS IN WHO GRADE II ASTROCYTOMAS. Neuro-Oncology, 2015, 17, v217.4-v217.	0.6	0
364	IMPS-14PROGNOSTIC ROLE OF REGULATORY T-CELLS IN PRIMARY AND RECURRENT MENINGIOMA. Neuro-Oncology, 2015, 17, v116.1-v116.	0.6	2
365	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. Neuropathology, 2015, 35, 538-544.	0.7	38
366	Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma. Glia, 2015, 63, 1850-1859.	2.5	13
367	Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. Oncotarget, 2015, 6, 13579-13590.	0.8	21
368	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. Cancer Cell, 2015, 27, 728-743.	7.7	933
369	Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis. Journal of Neuro-Oncology, 2015, 124, 265-273.	1.4	16
370	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. Acta Neuropathologica, 2015, 130, 419-434.	3.9	74
371	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. Acta Neuropathologica, 2015, 129, 867-873.	3.9	272
372	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathology and Applied Neurobiology, 2015, 41, 694-720.	1.8	83
373	Melanotic Tumors of the Nervous System are Characterized by Distinct Mutational, Chromosomal and Epigenomic Profiles. Brain Pathology, 2015, 25, 202-208.	2.1	66
374	<sc><i>BRAF V</i></sc><i>600</i><sc><i>E</i></sc> analysis for the differentiation of papillary craniopharyngiomas and <sc>R</sc>athke's cleft cysts. Neuropathology and Applied Neurobiology, 2015, 41, 733-742.	1.8	50
375	Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Modern Pathology, 2015, 28, 187-200.	2.9	134
376	Farewell to oligoastrocytoma: response to letters. Acta Neuropathologica, 2015, 129, 155-155.	3.9	7
377	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathologica, 2015, 129, 669-678.	3.9	277
378	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica, 2015, 130, 407-417.	3.9	237

#	ARTICLE	IF	CITATIONS
379	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. <i>New England Journal of Medicine</i> , 2015, 372, 2481-2498.	13.9	2,582
380	Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2015, 3, 22.	2.4	66
381	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. <i>Acta Neuropathologica</i> , 2015, 129, 679-693.	3.9	254
382	Glioblastoma: pathology, molecular mechanisms and markers. <i>Acta Neuropathologica</i> , 2015, 129, 829-848.	3.9	503
383	Brain tumour cells interconnect to a functional and resistant network. <i>Nature</i> , 2015, 528, 93-98.	13.7	787
384	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , 2015, 129, 133-146.	3.9	378
385	BRAF <sup>V600E</sup> -mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1596-1602.	0.5	94
386	Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway. <i>Glia</i> , 2015, 63, 78-90.	2.5	51
387	Proximity ligation assay evaluates IDH1R132H presentation in gliomas. <i>Journal of Clinical Investigation</i> , 2015, 125, 593-606.	3.9	35
388	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2001-2001.	0.8	9
389	Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in patients with a high risk low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2006-2006.	0.8	7
390	Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2007-2007.	0.8	1
391	Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma. <i>Oncotarget</i> , 2015, 6, 31050-31068.	0.8	52
392	Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme.. <i>Journal of Clinical Oncology</i> , 2015, 33, e13046-e13046.	0.8	0
393	Abstract LB-114: The INFORM personalized medicine study for high-risk pediatric cancer patients. , 2015, , .		0
394	Survival According to BRAF-V600 Tumor Mutations " An Analysis of 437 Patients with Primary Melanoma. <i>PLoS ONE</i> , 2014, 9, e86194.	1.1	42
395	BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. <i>Modern Pathology</i> , 2014, 27, 1028-1034.	2.9	96
396	Detection of BRAF <sup>V600E</sup> Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 71-75.	1.2	57

#	ARTICLE	IF	CITATIONS
397	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. <i>Neuro-Oncology</i> , 2014, 16, 1630-1638.	0.6	77
398	Predictive molecular markers in metastases to the central nervous system: recent advances and future avenues. <i>Acta Neuropathologica</i> , 2014, 128, 879-891.	3.9	54
399	Assessment and prognostic significance of the epidermal growth factor receptor vlll mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. <i>International Journal of Cancer</i> , 2014, 134, 2437-2447.	2.3	100
400	MAP kinase activity supported by BRAF V600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases. <i>Archives of Dermatological Research</i> , 2014, 306, 873-884.	1.1	11
401	mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 409-414.	3.3	152
402	Neurofibromin specific antibody differentiates malignant peripheral nerve sheath tumors (MPNST) from other spindle cell neoplasms. <i>Acta Neuropathologica</i> , 2014, 127, 565-572.	3.9	41
403	High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. <i>Lung Cancer</i> , 2014, 83, 83-89.	0.9	63
404	Molecular characterization of long-term survivors of glioblastoma using genome- and transcriptome-wide profiling. <i>International Journal of Cancer</i> , 2014, 135, 1822-1831.	2.3	117
405	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405.	7.7	627
406	Diagnostic Value of Immunohistochemistry for the Detection of the <i>BRAF</i> <sup>V600E</sup> Mutation in Papillary Thyroid Carcinoma: Comparative Analysis with Three DNA-Based Assays. <i>Thyroid</i> , 2014, 24, 858-866.	2.4	57
407	Nuclear relocation of <i>STAT</i> 6 reliably predicts <i>NAB2</i> – <i>STAT6</i> fusion for the diagnosis of solitary fibrous tumour. <i>Histopathology</i> , 2014, 65, 613-622.	1.6	101
408	Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas. <i>Neuro-Oncology</i> , 2014, 16, 914-923.	0.6	69
409	<i>BRAF</i> –Mutated Pleomorphic Xanthoastrocytoma is Associated with Temporal Location, Reticulin Fiber Deposition and <i>CD</i> 34 Expression. <i>Brain Pathology</i> , 2014, 24, 221-229.	2.1	72
410	Aberrant self-renewal and quiescence contribute to the aggressiveness of glioblastoma. <i>Journal of Pathology</i> , 2014, 234, 23-33.	2.1	53
411	<i>GRHL1</i> Acts as Tumor Suppressor in Neuroblastoma and Is Negatively Regulated by MYCN and HDAC3. <i>Cancer Research</i> , 2014, 74, 2604-2616.	0.4	54
412	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. <i>Acta Neuropathologica</i> , 2014, 128, 279-289.	3.9	191
413	Amplification and overexpression of <i>CMET</i> is a common event in brain metastases of non-small cell lung cancer. <i>Histopathology</i> , 2014, 65, 684-692.	1.6	25
414	Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. <i>Modern Pathology</i> , 2014, 27, 135-144.	2.9	49



#	ARTICLE	IF	CITATIONS
415	In situ proximity ligation assay to evaluate presentation of a mutated CD4 epitope in human glioma tissue. <i>Journal of Neuroimmunology</i> , 2014, 275, 35.	1.1	0
416	Mutant IDH1R132H bears a mutation-specific CD4 T cell epitope suitable for vaccination of human CNS tumors. <i>Journal of Neuroimmunology</i> , 2014, 275, 39.	1.1	0
417	A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 6304-6313.	3.2	111
418	International Society of Neuroanatomy & Neuroinformatics Consensus Guidelines for Nervous System Tumor Classification and Grading. <i>Brain Pathology</i> , 2014, 24, 429-435.	2.1	499
419	Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. <i>Acta Neuropathologica</i> , 2014, 128, 449-452.	3.9	36
420	TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 33.	3.5	74
421	D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 19.	2.4	72
422	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , 2014, 128, 561-571.	3.9	176
423	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. <i>Acta Neuropathologica</i> , 2014, 128, 551-559.	3.9	268
424	Enhancer hijacking activates GF1 family oncogenes in medulloblastoma. <i>Nature</i> , 2014, 511, 428-434.	13.7	520
425	A vaccine targeting mutant IDH1 induces antitumour immunity. <i>Nature</i> , 2014, 512, 324-327.	13.7	613
426	MGMT testing – the challenges for biomarker-based glioma treatment. <i>Nature Reviews Neurology</i> , 2014, 10, 372-385.	4.9	454
427	Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2006-2006.	0.8	2
428	Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2014-2014.	0.8	11
429	Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2017-2017.	0.8	3
430	Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. <i>Oncotarget</i> , 2014, 5, 1038-1051.	0.8	248
431	Abstract 3093: Unravelling the biology of aggressive and therapy-resistant embryonal tumors with multilayered rosettes (ETMR). , 2014, , .		0
432	Abstract 1889: Next-generation neuropathology - Improving diagnostic accuracy for brain tumors using DNA methylation array-based molecular profiling. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
433	Abstract 3094: Epigenetic classification of ependymal brain tumors across age groups. , 2014, , .		0
434	Interlaboratory comparison of IDH mutation detection. Journal of Neuro-Oncology, 2013, 112, 173-178.	1.4	59
435	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	9.4	674
436	Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and $\beta$ -KG. Acta Neuropathologica Communications, 2013, 1, 18.	2.4	54
437	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathologica, 2013, 126, 443-451.	3.9	304
438	Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathologica, 2013, 125, 891-900.	3.9	177
439	Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathologica, 2013, 125, 651-658.	3.9	324
440	Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathologica, 2013, 125, 351-358.	3.9	208
441	BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer. International Journal of Cancer, 2013, 133, 1624-1630.	2.3	93
442	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 2013, 126, 907-915.	3.9	254
443	AKT1E17K mutations cluster with meningotheial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. Acta Neuropathologica, 2013, 126, 757-762.	3.9	88
444	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672.	7.7	633
445	The Endogenous Tryptophan Metabolite and NAD+ Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress. Cancer Research, 2013, 73, 3225-3234.	0.4	126
446	Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. Journal of Neuroimmunology, 2013, 265, 106-116.	1.1	81
447	Prognostic or predictive value of <i>MGMT</i> promoter methylation in gliomas depends on <i>IDH1</i> mutation. Neurology, 2013, 81, 1515-1522.	1.5	211
448	Clonal BRAF Mutations in Melanocytic Nevi and Initiating Role of BRAF in Melanocytic Neoplasia. Journal of the National Cancer Institute, 2013, 105, 917-919.	3.0	92
449	Highly prevalent <i>TERT</i> promoter mutations in bladder cancer and glioblastoma. Cell Cycle, 2013, 12, 1637-1638.	1.3	123
450	Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Human Pathology, 2013, 44, 329-335.	1.1	77

#	ARTICLE	IF	CITATIONS
451	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	3.9	146
452	ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 80, 278-283.	0.9	59
453	Detection of BRAF p.V600E Mutations in Melanomas. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 94-100.	1.2	144
454	Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs. <i>Translational Oncology</i> , 2013, 6, 685-IN18.	1.7	25
455	Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2013, 18, 1416-1425.	2.2	62
456	Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. <i>Neuro-Oncology</i> , 2013, 15, 1405-1412.	0.6	53
457	Functional MHC Class II Is Upregulated in Neurofibromin-Deficient Schwann Cells. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1372-1375.	0.3	6
458	No Evidence for BRAF-V600E Mutations in Gastroesophageal Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 426-430.	0.6	12
459	BRAFV600E Immunohistochemistry Facilitates Universal Screening of Colorectal Cancers for Lynch Syndrome. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1592-1602.	2.1	125
460	Expression of BRAF V600E Mutant Protein in Epithelial Ovarian Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 159-164.	0.6	27
461	Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations. <i>Clinical Cancer Research</i> , 2013, 19, 5146-5157.	3.2	157
462	Targeting the BRAF V600E Mutation in Multiple Myeloma. <i>Cancer Discovery</i> , 2013, 3, 862-869.	7.7	202
463	Protein kinase C $\delta$ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 14735-14740.	3.3	43
464	Combined BRAFV600E-positive Melanocytic Lesions With Large Epithelioid Cells Lacking BAP1 Expression and Conventional Nevomelanocytes. <i>American Journal of Surgical Pathology</i> , 2013, 37, 193-199.	2.1	89
465	Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 61-65.	2.1	289
466	Chromogenic <i>in situ</i> Hybridization is a Reliable Alternative to Fluorescence <i>in situ</i> Hybridization for Diagnostic Testing of 1p and 19q Loss in Paraffin-Embedded Gliomas. <i>Brain Pathology</i> , 2013, 23, 311-318.	2.1	21
467	Immunohistochemical Analysis of BRAFV600E Expression of Primary and Metastatic Melanoma and Comparison With Mutation Status and Melanocyte Differentiation Antigens of Metastatic Lesions. <i>American Journal of Surgical Pathology</i> , 2013, 37, 413-420.	2.1	99
468	Sensitivity of Malignant Peripheral Nerve Sheath Tumor Cells to TRAIL Is Augmented by Loss of NF1 through Modulation of MYC/MAD and Is Potentiated by Curcumin through Induction of ROS. <i>PLoS ONE</i> , 2013, 8, e57152.	1.1	28

#	ARTICLE	IF	CITATIONS
469	A Novel, Diffusely Infiltrative Xenograft Model of Human Anaplastic Oligodendroglioma with Mutations in FUBP1, CIC, and IDH1. <i>PLoS ONE</i> , 2013, 8, e59773.	1.1	39
470	Nbn and Atm Cooperate in a Tissue and Developmental Stage-Specific Manner to Prevent Double Strand Breaks and Apoptosis in Developing Brain and Eye. <i>PLoS ONE</i> , 2013, 8, e69209.	1.1	17
471	Abstract LB-80: ATRX loss refines the classification of anaplastic glioma and is a favorable prognostic marker.., 2013, , .		1
472	Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. <i>EMBO Journal</i> , 2012, 31, 2629-2647.	3.5	110
473	Addressing Diffuse Glioma as a Systemic Brain Disease With Single-Cell Analysis. <i>Archives of Neurology</i> , 2012, 69, 523.	4.9	148
474	Application of a BRAF V600E Mutation-specific Antibody for the Diagnosis of Hairy Cell Leukemia. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1796-1800.	2.1	135
475	Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 844-850.	2.1	177
476	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. <i>Blood</i> , 2012, 120, 2700-2703.	0.6	589
477	Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas. <i>International Journal of Oncology</i> , 2012, 40, 2058-62.	1.4	23
478	Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate. <i>Acta Neuropathologica</i> , 2012, 124, 883-891.	3.9	58
479	BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. <i>Blood</i> , 2012, 120, e28-e34.	0.6	199
480	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. <i>Acta Neuropathologica</i> , 2012, 124, 439-447.	3.9	799
481	LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). <i>Acta Neuropathologica</i> , 2012, 124, 875-881.	3.9	115
482	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437.	7.7	1,551
483	Long-Term Outcome After Radiotherapy in Patients With Atypical and Malignant Meningiomasâ€”Clinical Results in 85 Patients Treated in a Single Institution Leading to Optimized Guidelines for Early Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 859-864.	0.4	128
484	Bone marrow biopsies of patients with hematopoietic and lymphoid disorders â€” epidemiology, chromosomal aberrations and molecular pathology. <i>Pathology Research and Practice</i> , 2012, 208, 510-517.	1.0	2
485	IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2012, 21, 194-197.	0.9	123
486	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. <i>Cell</i> , 2012, 148, 59-71.	13.5	743

#	ARTICLE	IF	CITATIONS
487	Nestin Expression Identifies Ependymoma Patients with Poor Outcome. <i>Brain Pathology</i> , 2012, 22, 848-860.	2.1	40
488	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. <i>Nature</i> , 2012, 482, 226-231.	13.7	2,129
489	Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 488-491.	0.6	51
490	Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event. <i>PLoS ONE</i> , 2012, 7, e41298.	1.1	43
491	Impaired Pten Expression in Human Malignant Peripheral Nerve Sheath Tumours. <i>PLoS ONE</i> , 2012, 7, e47595.	1.1	49
492	Dissecting the genomic complexity underlying medulloblastoma. <i>Nature</i> , 2012, 488, 100-105.	13.7	765
493	2-Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. <i>International Journal of Cancer</i> , 2012, 131, 766-768.	2.3	74
494	Epigenetically mediated downregulation of the differentiation-promoting chaperon protein CRABP2 in astrocytic gliomas. <i>International Journal of Cancer</i> , 2012, 131, 1963-1968.	2.3	18
495	No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. <i>Journal of Neuro-Oncology</i> , 2012, 109, 15-22.	1.4	66
496	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 515-527.	3.9	66
497	Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. <i>Acta Neuropathologica</i> , 2012, 123, 841-852.	3.9	77
498	CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. <i>Acta Neuropathologica</i> , 2012, 123, 853-860.	3.9	130
499	Detection of 2-Hydroxyglutarate in Formalin-Fixed Paraffin-Embedded Glioma Specimens by Gas Chromatography/Mass Spectrometry. <i>Brain Pathology</i> , 2012, 22, 26-31.	2.1	49
500	The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. <i>EMBO Molecular Medicine</i> , 2012, 4, 38-51.	3.3	81
501	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. <i>Acta Neuropathologica</i> , 2012, 123, 223-233.	3.9	204
502	Brain metastases: pathobiology and emerging targeted therapies. <i>Acta Neuropathologica</i> , 2012, 123, 205-222.	3.9	163
503	Abstract 3687: An integrative genomics approach identifies distinct molecular and epigenetic subgroups of pediatric glioblastoma. <i>Cancer Research</i> , 2012, 72, 3687-3687.	0.4	15
504	Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma. <i>PLoS ONE</i> , 2012, 7, e33449.	1.1	120

#	ARTICLE	IF	CITATIONS
505	Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase. PLoS ONE, 2012, 7, e47663.	1.1	42
506	Mutation specific antibodies: tool or dinosaur?. Oncotarget, 2012, 3, 907-908.	0.8	6
507	Clinical neuropathology practice news 2-2012: BRAF V600E testing. , 2012, 31, 64-66.		12
508	Abstract 3240: The Wnt secretion factor Evi/Wls/Gpr177 promotes glioma tumorigenesis. , 2012, , .		1
509	Abstract 4736: N-myc downstream regulated gene 1: A novel mediator of hypoxia-driven chemoresistance in glioblastoma. , 2012, , .		0
510	Abstract 1424: KCNJ2 comprises a marker of poor prognosis and a therapeutic target in non-WNT/non-SHH medulloblastoma. , 2012, , .		1
511	Abstract 1432: The heterogeneous genomic landscape of posterior fossa ependymoma. , 2012, , .		0
512	BRAF V600E Mutations in Multiple Myeloma: Clinical and Therapeutic Implications. Blood, 2012, 120, 4040-4040.	0.6	1
513	Adult Medulloblastoma Comprises Three Major Molecular Variants. Journal of Clinical Oncology, 2011, 29, 2717-2723.	0.8	215
514	An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature, 2011, 478, 197-203.	18.7	1,514
515	Improved Correlation of the Neuropathologic Classification According to Adapted World Health Organization Classification and Outcome After Radiotherapy in Patients With Atypical and Anaplastic Meningiomas. International Journal of Radiation Oncology Biology Physics, 2011, 81, 1415-1421.	0.4	59
516	The p53 Tumor Suppressor Is Stabilized by Inhibitor of Growth 1 (ING1) by Blocking Polyubiquitination. PLoS ONE, 2011, 6, e21065.	1.1	36
517	Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. Histopathology, 2011, 58, 1167-1172.	1.6	13
518	The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. Brain Pathology, 2011, 21, 74-87.	2.1	150
519	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. Cancer Cell, 2011, 20, 143-157.	7.7	494
520	Identification of diagnostic serum protein profiles of glioblastoma patients. Journal of Neuro-Oncology, 2011, 102, 71-80.	1.4	49
521	Prognostic stratification of gliomatosis cerebri by IDH1R132H and INA expression. Journal of Neuro-Oncology, 2011, 105, 219-224.	1.4	36
522	Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathologica, 2011, 121, 241-252.	3.9	124

#	ARTICLE	IF	CITATIONS
523	R132H-mutation of isocitrate dehydrogenase-1 is not sufficient for HIF-1 $\alpha$ upregulation in adult glioma. <i>Acta Neuropathologica</i> , 2011, 121, 279-281.	3.9	67
524	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 397-405.	3.9	914
525	Oncogenic FAM131B $\rightarrow$ BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 763-774.	3.9	211
526	Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. <i>Acta Neuropathologica</i> , 2011, 122, 11-19.	3.9	445
527	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. <i>Acta Neuropathologica</i> , 2011, 122, 637-650.	3.9	77
528	Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?. <i>Radiation Oncology</i> , 2011, 6, 115.	1.2	99
529	Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas. <i>Glia</i> , 2011, 59, 1200-1204.	2.5	44
530	Molecular signatures classify astrocytic gliomas by IDH1 mutation status. <i>International Journal of Cancer</i> , 2011, 128, 1095-1103.	2.3	75
531	Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. <i>International Journal of Cancer</i> , 2011, 128, 1981-1988.	2.3	44
532	Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?. <i>Clinical Cancer Research</i> , 2011, 17, 4588-4599.	3.2	179
533	FSTL5 Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3852-3861.	0.8	143
534	Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF- $\beta$ 2. <i>Clinical Cancer Research</i> , 2011, 17, 4296-4308.	3.2	290
535	The efficacy of bipolar and multipolar radiofrequency ablation of lung neoplasms – results of an ablate and resect study. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 39, 968-973.	0.6	38
536	Abstract 4699: Oncogenic fusion genes resulting from 7q34 deletions constitute a novel mechanism of MAPK pathway activation in pilocytic astrocytoma. , 2011, , .		0
537	Abstract 3453: Induction of differentiation in high-risk ependymoma stem-like cells by treatment with the HDAC inhibitor Vorinostat. , 2011, , .		0
538	Presence of Alternative Lengthening of Telomeres Mechanism in Patients With Glioblastoma Identifies a Less Aggressive Tumor Type With Longer Survival. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 729-736.	0.9	76
539	Medulloblastoma Harbor Somatic Mitochondrial DNA Mutations in the D-loop Region. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, 156-159.	0.3	14
540	Application of Mutant IDH1 Antibody to Differentiate Diffuse Glioma From Nonneoplastic Central Nervous System Lesions and Therapy-induced Changes. <i>American Journal of Surgical Pathology</i> , 2010, 34, 1199-1204.	2.1	108

#	ARTICLE	IF	CITATIONS
541	IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody. <i>Haematologica</i> , 2010, 95, 1797-1798.	1.7	13
542	Chemoradiotherapy of Newly Diagnosed Glioblastoma With Intensified Temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 670-676.	0.4	50
543	Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. <i>Acta Neuropathologica</i> , 2010, 120, 253-260.	3.9	129
544	Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. <i>Acta Neuropathologica</i> , 2010, 120, 261-267.	3.9	47
545	Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. <i>Acta Neuropathologica</i> , 2010, 120, 707-718.	3.9	719
546	Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model. <i>Journal of Neuro-Oncology</i> , 2010, 98, 11-19.	1.4	31
547	Increased levels of 2-hydroxyglutarate in AML patients with IDH1 R132H and IDH2 R140Q mutations. <i>European Journal of Haematology</i> , 2010, 85, 457-459.	1.1	39
548	Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. <i>Leukemia Research</i> , 2010, 34, 1091-1093.	0.4	18
549	PCR and Restriction Endonuclease Based Detection of IDH1 Mutations. <i>Brain Pathology</i> , 2010, 20, 298-300.	2.1	58
550	Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors. <i>Brain Pathology</i> , 2010, 20, 245-254.	2.1	463
551	The 4q12 Amplicon in Malignant Peripheral Nerve Sheath Tumors: Consequences on Gene Expression and Implications for Sunitinib Treatment. <i>PLoS ONE</i> , 2010, 5, e11858.	1.1	25
552	Defective p53 antiangiogenic signaling in glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 894-907.	0.6	14
553	Molecular Staging of Intracranial Ependymoma in Children and Adults. <i>Journal of Clinical Oncology</i> , 2010, 28, 3182-3190.	0.8	210
554	TP53 Mutation Is Frequently Associated With CTNNB1 Mutation or MYCN Amplification and Is Compatible With Long-Term Survival in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 5188-5196.	0.8	100
555	Role of LIM and SH3 Protein 1 (LASP1) in the Metastatic Dissemination of Medulloblastoma. <i>Cancer Research</i> , 2010, 70, 8003-8014.	0.4	62
556	Inositol-requiring enzyme 1 is a key regulator of angiogenesis and invasion in malignant glioma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15553-15558.	3.3	262
557	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. <i>Clinical Cancer Research</i> , 2010, 16, 3240-3252.	3.2	175
558	Carbon ion radiation therapy for high-risk meningiomas. <i>Radiotherapy and Oncology</i> , 2010, 95, 54-59.	0.3	75



#	ARTICLE	IF	CITATIONS
559	Adult and Pediatric Medulloblastomas Are Genetically Distinct and Require Different Algorithms for Molecular Risk Stratification. <i>Journal of Clinical Oncology</i> , 2010, 28, 3054-3060.	0.8	136
560	Abstract 31: Subgroup-specific molecular alterations may explain the tremendous clinical heterogeneity of intracranial ependymoma. , 2010, , .		0
561	Abstract 1178: Identification of a novel BRAF fusion partner in pilocytic astrocytoma. , 2010, , .		0
562	Histone Deacetylase 8 in Neuroblastoma Tumorigenesis. <i>Clinical Cancer Research</i> , 2009, 15, 91-99.	3.2	335
563	Quercetin promotes degradation of survivin and thereby enhances death-receptor-mediated apoptosis in glioma cells. <i>Neuro-Oncology</i> , 2009, 11, 122-131.	0.6	117
564	Reversal of P-glycoprotein-mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3. <i>Cancer Research</i> , 2009, 69, 416-421.	0.4	89
565	Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. <i>Neuro-Oncology</i> , 2009, 11, 803-818.	0.6	43
566	Epigenetic Silencing of <i>Death Receptor 4</i> Mediates Tumor Necrosis Factor-related Apoptosis-Inducing Ligand Resistance in Gliomas. <i>Clinical Cancer Research</i> , 2009, 15, 5457-5465.	3.2	52
567	Somatic mitochondrial mutations in pilocytic astrocytoma. <i>Cancer Genetics and Cytogenetics</i> , 2009, 192, 30-35.	1.0	23
568	Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 229-238.	1.5	24
569	Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 558-568.	1.5	13
570	Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. <i>Acta Neuropathologica</i> , 2009, 117, 457-464.	3.9	106
571	Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-8 by promoter methylation. <i>Acta Neuropathologica</i> , 2009, 117, 445-456.	3.9	88
572	Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. <i>Acta Neuropathologica</i> , 2009, 118, 401-405.	3.9	255
573	Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. <i>Acta Neuropathologica</i> , 2009, 118, 469-474.	3.9	1,020
574	Monoclonal antibody specific for IDH1 R132H mutation. <i>Acta Neuropathologica</i> , 2009, 118, 599-601.	3.9	380
575	Decreased expression of the active subunit of the cystine/glutamate antiporter xCT is associated with loss of heterozygosity of 1p in oligodendroglial tumours WHO grade II. <i>Histopathology</i> , 2009, 54, 241-247.	1.6	4
576	Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas. <i>Modern Pathology</i> , 2009, 22, 1263-1271.	2.9	13

#	ARTICLE	IF	CITATIONS
577	<i>RASSF1A</i>, <i>BLU, NORE1A</i>, <i>PTEN</i> and <i>MGMT</i> Expression and Promoter Methylation in Gliomas and Glioma Cell Lines and Evidence of Deregulated Expression of <i>de novo DNMTs</i>. Brain Pathology, 2009, 19, 279-292.	2.1	47
578	Molecular Pathology of Oligodendroglial Tumors. Recent Results in Cancer Research, 2009, 171, 25-49.	1.8	16
579	Intraoperative Radiofrequency Ablation of Lung Metastases and Histologic Evaluation. Annals of Thoracic Surgery, 2009, 87, 379-384.	0.7	29
580	NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide. Journal of Clinical Oncology, 2009, 27, 5874-5880.	0.8	743
581	Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network. Journal of Clinical Oncology, 2009, 27, 5743-5750.	0.8	534
582	The Inhibitor of Growth 1 (ING1) Is Involved in Trichostatin A-Induced Apoptosis and Caspase 3 Signaling in p53-Deficient Glioblastoma Cells. Oncology Research, 2009, 18, 469-480.	0.6	17
583	Hereditary Tumor Syndromes and Gliomas. Recent Results in Cancer Research, 2009, 171, 83-102.	1.8	40
584	The Inhibitor of Growth 1 (ING1) Proteins Suppress Angiogenesis and Differentially Regulate Angiopoietin Expression in Glioblastoma Cells. Oncology Research, 2009, 18, 95-105.	0.6	11
585	Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. Journal of Neuro-Oncology, 2008, 86, 23-30.	1.4	12
586	Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. Journal of Molecular Histology, 2008, 39, 553-560.	1.0	10
587	Accumulation of genomic aberrations during clinical progression of medulloblastoma. Acta Neuropathologica, 2008, 116, 383-390.	3.9	23
588	Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica, 2008, 116, 597-602.	3.9	910
589	The Evolution of Our Understanding on Glioma. Brain Pathology, 2008, 18, 455-463.	2.1	23
590	Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR. BMC Cancer, 2008, 8, 61.	1.1	54
591	Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma. Cancer Cell, 2008, 13, 235-248.	7.7	281
592	The flavonoid kaempferol sensitizes human glioma cells to TRAIL-mediated apoptosis by proteasomal degradation of survivin. Molecular Cancer Therapeutics, 2008, 7, 3566-3574.	1.9	92
593	EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro-Oncology, 2008, 10, 946-957.	0.6	71
594	Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme. Neuro-Oncology, 2007, 9, 291-297.	0.6	49

#	ARTICLE	IF	CITATIONS
595	Long-term survival with glioblastoma multiforme. <i>Brain</i> , 2007, 130, 2596-2606.	3.7	748
596	Association between fluorine-18 <sup>18F</sup> -labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. <i>Journal of Neurosurgery</i> , 2007, 106, 633-637.	0.9	25
597	Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker?. <i>Clinical Cancer Research</i> , 2007, 13, 6933-6937.	3.2	131
598	Occurrence of a Spinal Anaplastic Pilocytic Astrocytoma and a Supratentorial PNET in an Adolescent. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 832-835.	0.3	2
599	Expression of PACAP and glutamate transporter proteins in satellite oligodendrocytes of the human CNS. <i>Regulatory Peptides</i> , 2007, 142, 52-59.	1.9	25
600	Onconase induces caspase-independent cell death in chemoresistant neuroblastoma cells. <i>Cancer Letters</i> , 2007, 250, 107-116.	3.2	45
601	MMP-13, p53 in the Progression of Malignant Peripheral Nerve Sheath Tumors. <i>Neoplasia</i> , 2007, 9, 671-677.	2.3	53
602	DNA hypermethylation and Aberrant Expression of the <i>EMP3</i> Gene at 19q13.3 in Human Gliomas. <i>Brain Pathology</i> , 2007, 17, 363-370.	2.1	47
603	Granulomatous tissue response in germinoma, a diagnostic pitfall in endoscopic biopsy. <i>Neuropathology</i> , 2007, 27, 127-132.	0.7	23
604	Intracranial Thermotherapy using Magnetic Nanoparticles Combined with External Beam Radiotherapy: Results of a Feasibility Study on Patients with Glioblastoma Multiforme. <i>Journal of Neuro-Oncology</i> , 2007, 81, 53-60.	1.4	632
605	Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. <i>Journal of Neuro-Oncology</i> , 2007, 82, 187-192.	1.4	76
606	Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells. <i>Clinical and Experimental Metastasis</i> , 2007, 24, 57-66.	1.7	38
607	A new clinico-pathological classification system for mesial temporal sclerosis. <i>Acta Neuropathologica</i> , 2007, 113, 235-244.	3.9	321
608	Cellular localization of pituitary adenylate cyclase-activating peptide (PACAP) following traumatic brain injury in humans. <i>Acta Neuropathologica</i> , 2007, 113, 683-693.	3.9	24
609	Decreased Expression of Glutamate Transporters in Astrocytes after Human Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2006, 23, 1518-1528.	1.7	124
610	A role for $\beta$ -melanocyte-stimulating hormone in human body-weight regulation. <i>Cell Metabolism</i> , 2006, 3, 141-146.	7.2	171
611	A Rapid and Sensitive Protocol for Competitive Reverse Transcriptase (cRT) PCR Analysis of Cellular Genes. <i>Brain Pathology</i> , 2006, 8, 13-18.	2.1	42
612	NF2 Mutations in Secretory and Other Rare Variants of Meningiomas. <i>Brain Pathology</i> , 2006, 16, 15-19.	2.1	56

#	ARTICLE	IF	CITATIONS
613	45- YEAR-OLD MALE WITH SYMPTOMATIC MASS IN THE FRONTAL LOBE. <i>Brain Pathology</i> , 2006, 16, 89-90.	2.1	5
614	The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. <i>Journal of Neuro-Oncology</i> , 2006, 78, 7-14.	1.4	409
615	Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 428-432.	3.3	91
616	Increased expression of avian erythroblastosis virus E26 oncogene homolog 1 in World Health Organization grade 1 meningiomas is associated with an elevated risk of recurrence and is correlated with the expression of its target genes matrix metalloproteinase-2 and MMP-9. <i>Cancer</i> , 2006, 107, 1365-1372.	2.0	28
617	Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. <i>International Journal of Cancer</i> , 2006, 119, 792-800.	2.3	66
618	Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. <i>Carcinogenesis</i> , 2006, 27, 664-671.	1.3	89
619	Chromosome 22 tiling-path array-CGH analysis identifies germ-line- and tumor-specific aberrations in patients with glioblastoma multiforme. <i>Genes Chromosomes and Cancer</i> , 2005, 44, 161-169.	1.5	30
620	Mutation analysis of DKK1 and in vivo evidence of predominant p53-independent DKK1 function in gliomas. <i>Acta Neuropathologica</i> , 2005, 109, 314-320.	3.9	12
621	PIK3CA mutations in glioblastoma multiforme. <i>Acta Neuropathologica</i> , 2005, 109, 639-642.	3.9	85
622	Pilocytic astrocytoma presenting as primary diffuse leptomeningeal gliomatosis: report of a unique case and review of the literature. <i>Acta Neuropathologica</i> , 2005, 110, 306-311.	3.9	22
623	Alterations of cell cycle regulators in gliomatosis cerebri. <i>Journal of Neuro-Oncology</i> , 2005, 72, 115-122.	1.4	28
624	Assessment of tumor cell invasion factors in gliomatosis cerebri. <i>Journal of Neuro-Oncology</i> , 2005, 73, 109-115.	1.4	13
625	Estimating cancer survival and clinical outcome based on genetic tumor progression scores. <i>Bioinformatics</i> , 2005, 21, 2438-2446.	1.8	46
626	The transcription factor Ets-1 is expressed in human amniochorionic membranes and is up-regulated in term and preterm premature rupture of membranes. <i>Journal of Perinatal Medicine</i> , 2005, 33, 314-9.	0.6	6
627	Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. <i>International Journal of Oncology</i> , 2005, 27, 1029.	1.4	26
628	Laser-assisted microdissection, techniques and applications in pathology (Review). <i>International Journal of Molecular Medicine</i> , 2005, 15, 763.	1.8	7
629	Molecular Genetic Analysis of Oligodendroglial Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 10-14.	0.9	49
630	Patients with High-Grade Gliomas Harboring Deletions of Chromosomes 9p and 10q Benefit from Temozolomide Treatment. <i>Neoplasia</i> , 2005, 7, 883-893.	2.3	55

#	ARTICLE	IF	CITATIONS
631	Brain slice invasion model reveals genes differentially regulated in glioma invasion. <i>Biochemical and Biophysical Research Communications</i> , 2005, 336, 1227-1233.	1.0	26
632	Absence of Immunoglobulin Class Switch in Primary Lymphomas of the Central Nervous System. <i>American Journal of Pathology</i> , 2005, 166, 1773-1779.	1.9	47
633	Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. <i>Acta Neuropathologica</i> , 2004, 107, 159-168.	3.9	50
634	Molecular pathogenesis of oligodendroglial tumors. <i>Journal of Neuro-Oncology</i> , 2004, 70, 161-181.	1.4	99
635	Pathology and molecular genetics of oligodendroglial tumors. <i>Journal of Molecular Medicine</i> , 2004, 82, 638-655.	1.7	44
636	Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors. <i>Human Mutation</i> , 2004, 23, 134-146.	1.1	97
637	Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytoma. <i>International Journal of Cancer</i> , 2004, 108, 839-844.	2.3	26
638	No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. <i>International Journal of Cancer</i> , 2004, 109, 476-479.	2.3	32
639	Pdgfr- $\beta$ in 1p/19q LOH oligodendrogliomas. <i>International Journal of Cancer</i> , 2004, 112, 1081-1082.	2.3	10
640	Subclassification of Nerve Sheath Tumors by Gene Expression Profiling. <i>Brain Pathology</i> , 2004, 14, 258-264.	2.1	42
641	Ligands for PPAR $\gamma$ 3 and RAR Cause Induction of Growth Inhibition and Apoptosis in Human Glioblastomas. <i>Journal of Neuro-Oncology</i> , 2003, 65, 107-118.	1.4	52
642	Analysis of TP53 and PTEN in gliomatosis cerebri. <i>Acta Neuropathologica</i> , 2003, 105, 529-536.	3.9	29
643	Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. <i>International Journal of Cancer</i> , 2003, 106, 74-77.	2.3	21
644	No preferential loss of paternal 19q alleles in oligodendroglial tumors. <i>Annals of Neurology</i> , 2003, 54, 256-258.	2.8	10
645	Differential Concentration-Dependent Effects of Prolonged Norepinephrine Infusion on Intraparenchymal Hemorrhage and Cortical Contusion in Brain-Injured Rats. <i>Journal of Neurotrauma</i> , 2003, 20, 1327-1337.	1.7	4
646	Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review). <i>International Journal of Oncology</i> , 2003, 23, 857.	1.4	13
647	Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. <i>Cancer Research</i> , 2003, 63, 1602-7.	0.4	617
648	Genetic Alterations Commonly Found in Diffusely Infiltrating Cerebral Gliomas Are Rare or Absent in Pleomorphic Xanthoastrocytomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2002, 61, 1092-1099.	0.9	53

#	ARTICLE	IF	CITATIONS
649	Impact of Genotype and Morphology on the Prognosis of Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2002, 61, 321-328.	0.9	184
650	Genetic Signature of Oligoastrocytomas Correlates with Tumor Location and Denotes Distinct Molecular Subsets. American Journal of Pathology, 2002, 161, 313-319.	1.9	171
651	Decreased hemispheric Aquaporin-4 is linked to evolving brain edema following controlled cortical impact injury in rats. Neuroscience Letters, 2002, 324, 105-108.	1.0	121
652	The SRCR/SID region of DMBT1 defines a complex multi-allele system representing the major basis for its variability in cancer. Genes Chromosomes and Cancer, 2002, 35, 242-255.	1.5	39
653	Rare mutations of the DMBT1 gene in human astrocytic gliomas. Oncogene, 2002, 21, 5956-5959.	2.6	24
654	Mutational analysis of INI1 in sporadic human brain tumors. Acta Neuropathologica, 2001, 101, 479-482.	3.9	31
655	Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1. Acta Neuropathologica, 2001, 102, 69-74.	3.9	50
656	Analysis of the TSC2 gene in human medulloblastoma. Acta Neuropathologica, 2001, 102, 380-384.	3.9	7
657	Subtyping of oligo-astrocytic tumours by comparative genomic hybridization. Journal of Pathology, 2001, 194, 81-87.	2.1	55
658	Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS genes in sporadic and radiation-induced human meningiomas. International Journal of Cancer, 2001, 94, 218-221.	2.3	80
659	Early expression of glutamate transporter proteins in ramified microglia after controlled cortical impact injury in the rat. Glia, 2001, 35, 167-179.	2.5	117
660	TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. Journal of Neuro-Oncology, 2001, 52, 263-272.	1.4	39
661	Cloning and characterization of the human GFRA2 locus and investigation of the gene in Hirschsprung disease. Human Genetics, 2001, 108, 409-415.	1.8	17
662	Loss of NF1 Alleles Distinguish Sporadic from NF1-Associated Pilocytic Astrocytomas. Journal of Neuropathology and Experimental Neurology, 2001, 60, 917-920.	0.9	113
663	Malignant transformation of a gangliocytoma/ganglioglioma into a glioblastoma multiforme: a molecular genetic analysis. Journal of Neurosurgery, 2001, 95, 138-142.	0.9	58
664	Clonal Analysis in Glioblastoma with Epithelial Differentiation. Brain Pathology, 2001, 11, 39-43.	2.1	23
665	Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes and Cancer, 2000, 29, 16-25.	1.5	13
666	Molecular analysis of the TSC1 and TSC2 tumour suppressor genes in sporadic glial and glioneuronal tumours. Human Genetics, 2000, 107, 350-356.	1.8	41

#	ARTICLE	IF	CITATIONS
667	Long-term survival of glioblastoma multiforme: importance of histopathological reevaluation. <i>Journal of Neurology</i> , 2000, 247, 455-460.	1.8	57
668	Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 544-558.	0.9	137
669	Long survival and therapeutic responses in patient histologically disparate high-grade gliomas demonstrating chromosome 1p loss. <i>Journal of Neurosurgery</i> , 2000, 92, 983-990.	0.9	133
670	Low Frequency of SV40, JC and BK Polyomavirus Sequences in Human Medulloblastomas, Meningiomas and Ependymomas. <i>Brain Pathology</i> , 2000, 10, 85-92.	2.1	81
671	Chromosomal Imbalances in Brain Metastases of Solid Tumors. <i>Brain Pathology</i> , 2000, 10, 395-401.	2.1	60
672	Mapping of the chromosome 19q13.2 arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. <i>Genes Chromosomes and Cancer</i> , 2000, 29, 16-25.	1.5	74
673	Clonal Origin of Recurrent Meningiomas. <i>Brain Pathology</i> , 1999, 9, 645-650.	2.1	20
674	A case history of glioma progression. <i>Acta Neuropathologica</i> , 1999, 97, 525-532.	3.9	27
675	Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas. <i>Acta Neuropathologica</i> , 1999, 97, 547-551.	3.9	7
676	Analysis of the MEN1 gene in sporadic pituitary adenomas. , 1999, 188, 168-173.		37
677	Molecular Genetic Analysis of Ependymal Tumors. <i>American Journal of Pathology</i> , 1999, 155, 627-632.	1.9	226
678	Identification of Subgroups of High-grade Oligodendroglial Tumors by Comparative Genomic Hybridization. <i>Journal of Neuropathology and Experimental Neurology</i> , 1999, 58, 606-612.	0.9	83
679	Common Regions of Deletion on Chromosome 22q12.3-q13.1 and 22q13.2 In Human Astrocytomas Appear Related To Malignancy Grade. <i>Journal of Neuropathology and Experimental Neurology</i> , 1999, 58, 881-885.	0.9	57
680	Molecular Genetic Analysis as a Tool for Evaluating Stereotactic Biopsies of Glioma Specimens. <i>Journal of Neuropathology and Experimental Neurology</i> , 1999, 58, 40-45.	0.9	13
681	Differential patterns of molecular genetic alterations define subsets among glioblastomas and oligoastrocytomas. <i>Neuropathology</i> , 1998, 18, 145-153.	0.7	2
682	PTEN mutations in gliomas and glioneuronal tumors. <i>Oncogene</i> , 1998, 16, 2259-2264.	2.6	300
683	A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. <i>Oncogene</i> , 1998, 16, 2403-2406.	2.6	92
684	Expression of the ATM gene is significantly reduced in sporadic breast carcinomas. , 1998, 78, 306-309.		37

#	ARTICLE	IF	CITATIONS
685	Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses. , 1998, 79, 640-644.		153
686	Analysis of a polymorphism in the tuberous sclerosis (TSC2) gene does not predispose to schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 1998, 248, 314-315.	1.8	2
687	Clonality of multiple meningiomas. Journal of Neurosurgery, 1997, 86, 853-858.	0.9	77
688	p53 Accumulation Promotes Dephosphorylation and Proteolytic Cleavage of Retinoblastoma Protein in Human Malignant Glioma Cells. Cellular Physiology and Biochemistry, 1997, 7, 304-311.	1.1	6
689	Molecular Genetic Evidence for Subtypes of Oligoastrocytomas. Journal of Neuropathology and Experimental Neurology, 1997, 56, 1098-1104.	0.9	219
690	A Novel Splice Site Associated Polymorphism in the Tuberous Sclerosis 2 (TSC2) Gene May Predispose to the Development of Sporadic Gangliogliomas. Journal of Neuropathology and Experimental Neurology, 1997, 56, 806-810.	0.9	29
691	Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus. Oncogene, 1997, 14, 611-616.	2.6	109
692	DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3â€“26.1 is deleted in malignant brain tumours. Nature Genetics, 1997, 17, 32-39.	9.4	423
693	Tuberous sclerosis-like lesions in epileptogenic human neocortex lack allelic loss at the TSC1 and TSC2 regions. Acta Neuropathologica, 1997, 93, 93-96.	3.9	26
694	Genomic deletions in the BRCA1, BRCA2 and TP53 regions associate with low expression of the estrogen receptor in sporadic breast carcinoma. , 1997, 74, 322-325.		22
695	A Polymerase Chain Reaction-based Assay for the Rapid Detection of Gene Amplification in Human Tumors. Diagnostic Molecular Pathology, 1996, 5, 147-150.	2.1	27
696	Lack of prognostic relevance of alterations in the epidermal growth factor receptorâ€”transforming growth factor-Î± pathway in human astrocytic gliomas. Journal of Neurosurgery, 1996, 85, 634-641.	0.9	69
697	The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genetics and Cytogenetics, 1996, 88, 136-140.	1.0	57
698	A Model for the Molecular Pathogenesis of Astrocytic Gliomas. , 1996, , 173-186.		0
699	Evidence for Subarachnoid Spread in the Development of Multiple Meningiomas. Brain Pathology, 1995, 5, 11-14.	2.1	33
700	THE CHROMOSOME 19q GLIOMA TUMOR SUPPRESSOR GENE. Journal of Neuropathology and Experimental Neurology, 1995, 54, 439.	0.9	1
701	Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma. Journal of Neuropathology and Experimental Neurology, 1995, 54, 91-95.	0.9	306
702	Chromosome 19q Deletions in Human Gliomas Overlap Telomeric to D19S219 and May Target a 425 kb Region Centromeric to D19S112. Journal of Neuropathology and Experimental Neurology, 1995, 54, 622-626.	0.9	39



#	ARTICLE	IF	CITATIONS
703	Molecular pathways in the formation of gliomas. <i>Glia</i> , 1995, 15, 328-338.	2.5	227
704	Hereditary Tumor Syndromes of the Nervous System: Overview and Rare Syndromes. <i>Brain Pathology</i> , 1995, 5, 145-151.	2.1	53
705	MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. <i>Human Molecular Genetics</i> , 1994, 3, 1841-1845.	1.4	96
706	Deletion mapping of chromosome 19 in human gliomas. <i>International Journal of Cancer</i> , 1994, 57, 676-680.	2.3	90
707	The retinoblastoma gene is involved in malignant progression of astrocytomas. <i>Annals of Neurology</i> , 1994, 36, 714-721.	2.8	211
708	Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 1993, 86, 81-85.	3.9	93
709	Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis. <i>Brain Pathology</i> , 1993, 3, 19-26.	2.1	597
710	MOLECULAR GENETIC ALTERATIONS IN PEDIATRIC BRAIN STEM GLIOMAS. <i>Journal of Neuropathology and Experimental Neurology</i> , 1993, 52, 267.	0.9	2
711	Molecular Genetics of Pediatric Brain Stem Gliomas. Application of PCR Techniques to Small and Archival Brain Tumor Specimens. <i>Journal of Neuropathology and Experimental Neurology</i> , 1993, 52, 507-515.	0.9	91
712	Comparative Study of p53 Gene and Protein Alterations in Human Astrocytic Tumors. <i>Journal of Neuropathology and Experimental Neurology</i> , 1993, 52, 31-38.	0.9	203
713	Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. <i>Journal of Neurosurgery</i> , 1992, 77, 295-301.	0.9	185
714	Central neurocytoma: histopathological variants and therapeutic approaches. <i>Journal of Neurosurgery</i> , 1992, 76, 32-37.	0.9	210
715	Desmoplastic cerebral astrocytomas of infancy: A histopathologic, immunohistochemical, ultrastructural, and molecular genetic study. <i>Human Pathology</i> , 1992, 23, 1402-1409.	1.1	73
716	Location of N-methyl-N-2-nitro-N-nitrosoguanidine-induced gastrointestinal tumors correlates with thiol distribution. <i>Carcinogenesis</i> , 1983, 4, 879-883.	1.3	35